Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy A, Nilsonne U, Kreicbergs A, Aparisi T
Cancer Immunol Immunother. 1986;21(1):69-76. doi: 10.1007/BF00199380.
Lymphocyte-mediated lysis of autologous tumor cells (autologous lymphocyte cytotoxicity ALC) was tested at the time of surgery in 108 patients (46 squamous cell carcinomas of the lung, 25 adenocarcinomas of the lung, 19 soft tissue sarcomas and 18 osteosarcomas). The clinical course of these patients in relation to the test results has been published previously. The group was evaluated again after an extended observation time, now with a mean of 80.2 months (range 36-108). The test was rarely positive in patients with metastasis (2 out of 28 experiments). There was a correlation between the ALC results and the postsurgical clinical course for patients without detectable metastasis in that (1) a negative test was invariably a bad prognostic sign, i.e., all 32 patients with negative ALC died within 3 years (mean survival time 16.1 months). (2) The remission and survival times were longer for the ALC positive patients (p less than 0.001). (3) All 37 individuals who are alive at present without recurrence belong to the reactive group. The ALC results correlated with the clinical course in 88% of patients. The correlation was highest for the groups of soft tissue sarcoma and adenocarcinoma of the lung. There was no correlation between killing of K562 cells and ALC, or between lymphoproliferative response to PHA and ALC reactivity.
在手术时对108例患者(46例肺鳞状细胞癌、25例肺腺癌、19例软组织肉瘤和18例骨肉瘤)进行了淋巴细胞介导的自体肿瘤细胞裂解(自体淋巴细胞细胞毒性,ALC)检测。这些患者的临床病程与检测结果的关系此前已发表。在延长观察期后再次对该组进行评估,此时平均观察期为80.2个月(范围36 - 108个月)。在有转移的患者中该检测很少呈阳性(28次实验中有2次)。对于无可检测转移的患者,ALC结果与术后临床病程之间存在相关性,即:(1)检测呈阴性始终是不良预后标志,也就是说,所有32例ALC阴性的患者在3年内死亡(平均生存时间16.1个月)。(2)ALC阳性患者的缓解期和生存时间更长(p < 0.001)。(3)目前所有存活且无复发的37人均属于反应性组。88%的患者中ALC结果与临床病程相关。在软组织肉瘤和肺腺癌组中相关性最高。K562细胞杀伤与ALC之间、对PHA的淋巴细胞增殖反应与ALC反应性之间均无相关性。